Kamada

KMDAPhase 3

Rehovot, IsraelFounded 1990kamada.com

Kamada is a vertically integrated biopharmaceutical company with a dual focus on commercial plasma-derived products and a pipeline of innovative therapeutics. Its flagship product, Glassia®, is an FDA-approved intravenous treatment for alpha-1 antitrypsin deficiency. The company leverages its manufacturing expertise to advance a pipeline of inhaled and plasma-derived therapies, while also engaging in strategic partnerships and contract development and manufacturing (CDMO) services.

Market Cap

$490.3M

Founded

1990

Employees

300-500

Focus

Biotech

KMDA · Stock Price

USD 8.50+2.83 (+49.91%)

Historical price data

AI Company Overview

Technology Platform

Proprietary protein purification, viral inactivation, and formulation technologies for plasma-derived and recombinant therapeutics, with a focus on developing inhaled protein delivery systems.

Pipeline Snapshot

16 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Cytogam	Cytomegalovirus (CMV) Infection	Approved
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months	Cytomegalovirus	Approved
KamRAB - HRIG	Rabies	Phase 3
Alpha 1-Antitrypsin + Placebo	Alpha 1-Antitrypsin Deficiency	Phase 3
Kamada AAT for inhalation	Emphysema	Phase 2/3

Opportunities

The primary growth opportunity is the successful launch of Inhaled AAT for AATD, which could capture significant market share from IV therapy and expand the treatable patient population.

Additional opportunities include label expansion of Inhaled AAT into Bronchiolitis Obliterans Syndrome (BOS) and growth of the high-margin CDMO business leveraging the company's specialized manufacturing expertise.

Risk Factors

Key risks include clinical failure or delays in the pivotal Phase 3 INHALE-3 trial for Inhaled AAT, regulatory hurdles for approval, challenges in commercializing a new therapy against established IV competitors, and dependence on strategic partners (Takeda, Kedrion) for a large portion of revenue.

Competitive Landscape

Kamada competes with Grifols, CSL Behring, and Takeda in the IV AAT market. In the emerging inhaled AAT segment, CSL Behring is the main direct competitor. Kamada differentiates itself through its proprietary inhaled formulation technology, vertical integration (in-house manufacturing), and established commercial footprint in the AATD space.

Publications

Patents

Pipeline